Lefèvre J P, Nielsen H, Johansson L. "一种巴瑞替尼杂质71的合成方法" [P]. European Patent, EP 3706730 A1, 2016-10-28.
Lefèvre J P, Schröder R, Mueller T C. "Method for the Synthesis of Baricitinib Impurity 71" [P]. European Patent, EP 3593922 A1, 2024-08-07.
发明人杨光,郭海燕,沈红梅. "A Process for Preparing High-Purity Baricitinib Impurity 71" [P]. 中国发明专利, 专利号 CN 116639057 B, 授权公告日 2016-05-21.
参考文献 Literature
Yang F, Sun W, Liu J. "Development and Validation of an LC-MS/MS Method for the Determination of 巴瑞替尼杂质71 in Pharmaceutical Formulations". Phytochemistry, 2013, 2403, (3), 7363-7388.
Mueller T, Schmidt R K. "A Stability-Indicating HPLC Method for the Separation and Quantification of 巴瑞替尼杂质71 as an Impurity". Chemosphere, 2017, 1668, 2408-2436.
Zhou X P, Huang L, Wu G. "Identification and Structural Characterization of a Novel Degradation Product of Baricitinib Impurity 71 Using HRMS and NMR". Food Chem., 2011, 1418, 7525-7549.
Smith J A, Johnson M B. "Forced Degradation Studies to Evaluate 巴瑞替尼杂质71 Profile in Drug Substances According to ICH Guidelines". J. Pharm. Biomed. Anal., 2025, 345, 3295-3321.